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1111-138 Why ICD Pat ients  With Heart  Fai lure (Class II-IV) Are 
Hospitalized: Do the Reasons Differ for Patients Who 
Are Treated With Cardlec Reeynchronizatlon Therapy? 
John P. Boehmer. Teresa DeMarco, Brian E. Jaski, Mark D. Carlson, Vicki L. Rathbun, 
Chelsey M, Schmeichel, Guidant Corporation, St. Paul, Minnesota. 
Background: Cardiac resynchronization therapy (CRT) is currently being tested as an 
adjunct therapy to treat heart failure (HF). The VENTAK CHF/CONTAK CD study, a multi- 
center double-blind study, enrolled patients with HF who also met the general indications 
for an ICD, It is not known if this HF population that also requires an ICD is hospitalized 
for different reasons than the HF population as a whole or if CRT changes the rate or rea- 
sons for hospitalization, 
Methods: 501 patients (Age:66 _+ 10 years, QRS:158 ms + 26, NYHA Class III 58%, 
LVEF 21,5 ± 6,6%, Ischemic etiology 68,9%) were implanted with a CRT/ICD system and 
were randomized to CRT or no CRT. The reason for all hospitalizations were adjudicated 
by an independent events committee that was blinded to pacing mode, and were classi- 
fied as CHF related, other cardiac or non-cardiac, 
Results: There were 231 hospitalizations for ICD patients with symptomatic HF. The 
addition of CRT did not significantly change the rate of hospitalizations or the reasons for 
being hospitalized. 
CRT CRT No CRT No CRT Total Total 
Reason for Hospitalization Patients Events Patients Events Patients Events 
CHF 32 50 39 56 71 106 
Cardiac - other 20 40 25 31 45 71 
Noncardiac 26 30 19 24 45 54 
Total 66 120 70 111 136 231 
Conclusion: CRT does not effect the frequency or reason of hospitalization in patients 
with heart failure receiving an ICD. The most common reason for hospitalization is heart 
failure. 
1111-139 Long-Term Improvement in Functional Statue, Quality 
of Life and Exercise Capac i ty  With Cardiac 
Reeynchronization Therapy: The MIRACLE Trial 
Experience 
William T. Abraham, Westby Fisher, Andrew Smith, David DeLurgio, Angel Leon, Evan 
Loh, Dusan Kocovic, Alfredo Clavell, David Hayes, Anthony Tang, Ven Manda, Susan 
Petersen-Stajskal, University of Kentucky, Lexington, Kentucky, Crewford Long/Emory 
Univ, Univ of Pennsylvania, Mayo Clinic, Uoiv of Ottawa, Medtronic. 
Background: Moderate-to-severe Congestive Heart Failure (CHF) patients (pts) with a 
prolonged QRS duration(>130 ms) enrolled in the Multicenter lnSync Randomized Con- 
trolled Evaluation (MIRACLE) Trial improved their functional status, quality of life and 
exercise tolerance during a 6 month double-blind evaluation of cardiac resynchronization 
therapy (CRT). The purpose of this analysis is to examine the long-term impact of CRT 
on the endpoints of Six-minute Hall Walk Distance (HWK), Minnesota Living with Heart 
Failure Quality of Life Score (QOL), NYHA Functional Class (NYHA) and Exercise Dura- 
tion (EXT) on a Treadmill. 
Methods: Pts that received 12 months of CRT in the MIRACLE trial were included in this 
evaluation. Endpoints were assessed using pts as their own controls. All tests of signfi- 
cance are based on the Wilcoxon Signed Rank Test. 
Results: 67 pts received CRT for a period of 12 rods (mean age(years): 62.4 ± 11.7; 
LVEF (%): 22.4 ± 5.8; LVEDD (ram): 69.7 ± 10.5; 75% male; ORS duration (ms): 164 ± 
18. Improvements in HWK, QOL, NYHA and EXT from baseline to 6 months and base- 
line to 12 months are shown in the Table. 
Endpoint Baseline to 6 months p-value Baseline to 12 p-value 
Median Change (intar-quartile months 
range) Median Change 
( inter-quartile range) 
HWK (meters) 61.5 < 0.001 42.8 <0.001 
(15.6,107.7) (-15.1,115.6) 
QOL score - 22.5 < 0.001 -18 < 0.001 
(-42, -5.7) (-43.5, -7) 
NHYA class - 1.0 < 0.001 -1.0 < 0.001 
(-1.0, 0) (-2.0, -1.0) 
EXT (seconds) 120.5 < 0.001 106 0.007 
(40, 195) (14, 216) 
In addition, 57 pts originally randomized to the no-CRT group for the first 6 months of the 
study subsequently received 6 months of CRT. HWK, QOL, NYHA and EXT were all 
improved at 12 months as compared to Baseline (p<O.05) 
Conclusions: In pts with symptomatic CHF, systolic dysfunction and a prolonged QRS, 
CRT offers a sustained, long term improvement in patient well-being and exercise capac- 
ity. 
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1111-140 Lower Sinus Rate Af ter  In i t iat ion of  Left  Ventricular 
Pacing in Patients With Left  Bundle Branch Block and 
Advanced Heart Failure 
Andreas Schuchert. Muhammet All Aydin, Thomas Meinertz, University-Hospital 
Hamburg-Eppendorf, Hamburg, Germany. 
The hypothesis was that the improvement of left ventricular pacing in patients with 
advanced heart failure and left bundle branch block is associated with changes of sinus 
rate. The distribution of the sinus rate at month 1 stored in the rate histogram of the pace- 
maker was compared to the findings at month 12. The study included 31 patients with 
advanced heart failure and left bundle branch block. All patients received a specially 
designed pacing lead, which was placed in a side branch of the coronary sinus for left 
ventricular pacing. The lead was connected to a DDD pacemaker (Affinity DR, St. Jude 
Medical) in 8 and to a biventricular three-chamber pacemaker (Frontier 3x2, St. Jude 
Medical) in 23 patients. The pacemaker stored in the diagnostic counters the atdal rate 
histogram, which summadzes the heart rates from 55 to 70 bpm (H1), from 71 to 90 bpm 
(H 2), from 91 to 110 bpm (H 3), and from 110 to 131 bpm (H 4). 
RESULTS: The patients had at implantation NYHA class III (n= 9) or class IV (n = 22). 
Follow-up at month 12 is completed in 19 patients who had NYHA class I in 15 and class 
II in 4 patients. At hospital discharge, 25 patients were programmed to the DDD and 6 
patients to the DDDR mode. Lower pacing rate was programmed to 62 ± 8 ppm and 
upper pacing rate to 113 ± 4 ppm. Besides the reduction of diuretics there was no rele- 
vant modification of the prescribed medication. The percentage of atrial pacing was 26 ± 
41% of the time at month 1 and 35 ± 45 % of the time at month 12. The distribution of the 
atrial rate was at month 1 55 ± 20 % (H1), 39 ± 18 % (H 2), 5 ± 2 % (H 3), 2 ± 1% (H 4), 
and at month 12 78 ± 21% (H 1; p<0.05 vs month 1), 17 ± 15 % (H 2; p<0.05 vs month 
1), 4 ± 3 % (H 3), and 1 ± 1% (H 4). The DDDR mode was programmed in additional 4 
patients because of chronotropic incompetence during follow-up. There were no signifi- 
cent differences between patients with left and biventdcular pacing. 
CONCLUSIONS: There was a significant 45% decrease in the frequency from 71 to 90 
bpm and a significant increase in the frequency from 55 to 70 bpm dudng the first year 
follow-up. The findings indicate that the symptomatic improvement after left ventricular 
pacing is associated with lower sinus rate. 
1111-159 Detectable T ropon in  T Level  Predicts  High Mortality in 
Patients With Heart Failure Undergoing Internal 
Defibrillator Implantation 
Ali F. Sonel. Alaa Shalaby, Joseph P. McConnell, Scott Hogen, Arthur M. Feldman, 
University of Pittsburgh and VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, 
Mayo Clinic, Rochester, Minnesota. 
Background: Tropenin levels have been demonstrated to predict cardiac events in 
patients with ischemic as well as non-ischemic cardiomyopathy (CM). Arrhythmic death 
remains a leading cause of mortality in patients with CM. While implantable cardiac 
defibrillator (ICD) devices have been demonstrated to favorably impact mortality in cer- 
tain subsets of patients with CM, their mortality remains high. 
Methods: In an effort to study the predictive value of baseline troponin levels in patients 
who are candidates for ICD devices we collected baseline blood samples for tropenin T 
(TnT) and CK-MB in 52 consecutive patients immediately before successful pectoral 
transvenous ICD implant. Patients with any clinical evidence of an acute coronary syn- 
drome during the preceding 2 weeks were excluded from the study. All patients received 
ICDs for standard clinical indications. They subsequently received routine clinical follow 
up care, Patients were divided into two groups based on their TnT level prior to implanta- 
tion. Patients with non-detectable TnT <0.01 ng/ml) were classified as Group A, Patients 
with detectable TnT (_>0.01 ng/ml) were classified as study Group B. Patients were then 
followed for total mortality 
Results: All patients were males with mean age 68+/- 10 years. Mean ejection fraction 
was 29 +1- 12% and 65% had ischemic cardiomyopathy. Mean follow up duration was 17 
+/- 8 months. None of the patients had abnormal CK-MB mass (Mean 1.7 +/- 1.1 ng/ml). 
There were 37 patients in Group A and 15 patients in Group B (TnT 0.013-0.146 ng/ml). 
There was no difference between the groups A and B in terms of age (68 vs. 69, p=NS), 
ejection fraction (30 vs. 29%, p=NS) or proportion of patients with ischemic cerdiomyope- 
thy (68 vs. 60%, p=NS). There were no early post-operative deaths (within 30 days). Dur- 
ing follow up 16 (31%) patients died. Group A patients had 16% mortality(6/37) 
compared to 67% mortality (10/15) in Group B (p<0.001). 
Concluelone: In a cohort of male patients with CM undergoing ICD implantation for stan- 
dard clinical indications, presence of detectable TnT is associated with high mortality 
despite ICD implantation. TnT may be a useful marker for risk stratification of patients 
with CM prior to ICD implantation. 
1111-160 Acute  Ef fects  of Biventrlculer Pacing on Noninvasive 
Parameters of Left Ventricular Systolic Function 
Zoran B. PoDoyj~, Richard A. Grimm, George Perlic, Edward Chinchoy, Jing Ping Sun, 
Erwan Donal, Nell L. Greenberg, Bruce Wilkoff, James D, Thomas, The Cleveland Clinic 
Foundation, Cleveland, Ohio, Cleveland, Ohio. 
While invasive studies have shown that biventricular (BiV) pacing improves left ventricu- 
lar (LV) function in selected heart failure patients, such techniques cannot be applied rou- 
tinely. We sought to assess acute effects of BiV pacing by noninvasive techniques. 
Methods: Sixteen patients enrolled in InSync trial (age 64 ± 9 years, 3 females, EF <35% 
and QRS >130 ms) were studied one to 6 months after pacemaker implantation during 
BiV pacing, and while ventricular pacing was inhibited. Regional strains and displace- 
ments of the interventdcular septum (IVS), LV free wall, and right ventricular (RV) free 
wall were obtained from Color Doppler tissue imaging in a four-chamber view (System 
Five, GE). Peak power index was calculated as a product of simultaneously acquired 
noninvasive blood pressure (Finapres, Ohmeda) and PW Doppler of the LV outflow tract. 
